mucosal immunization

mucosal immunization

immunization by presentation of the antigen on a mucosal surface, such as those of the nasal passages.
References in periodicals archive ?
The results showed that mIL-33 as a molecular adjuvant for pcDLzp3 DNA vaccine could enhance systemic Ab responses against ZP3 through mucosal immunization.
Mucosal immunization with a subunit respiratory syncytial virus vaccine in mice.
In September 2006, DelSite entered into a three-year CRADA with the Laboratory of Cellular Oncology at the National Cancer Institute (NCI) to determine if GelVac(TM) nasal powder delivery platform may be used for delivery of human papillomavirus virus-like particles (HPV VLP) vaccines in a powder dosage form for mucosal immunization.
Mucosal immunization with Helicobacter, CpG DNA, and cholera toxin is protective.
30) reported that mucosal immunization of African green monkeys with an attenuated parainfluenza virus expressing S protein resulted in production of neutralizing antibodies and protected animals from infection by challenge with SARS-CoV.
Therefore, chimeric HA-containing VLPs represent a potential approach for mucosal immunization for prevention of HIV infection.
PATH will fund EndoBiologics to complete preclinical research into process development, mucosal immunization, and evaluation of novel antigens for potential protection in animal models.
Modified polio virus vector--Genetically engineered poliovirus offers many attractive features for development as a vaccine vector for mucosal immunization.
In September 2006 DelSite entered into a three-year CRADA with the Laboratory of Cellular Oncology at the National Cancer Institute (NCI) to determine if GelVac(TM) nasal powder delivery platform is adaptable for delivering human papillomavirus virus-like particles (HPV VLP) vaccines in a powder dosage form for mucosal immunization.
Mucosal immunization with PspA can also elicit immunity to carriage (11,12).
In September of 2006, DelSite entered into a three-year CRADA with the Laboratory of Cellular Oncology at the National Cancer Institute (NCI) to determine if GelVac(TM) nasal powder delivery platform is adaptable for delivering human papillomavirus virus-like particles (HPV VLP) vaccines in a powder dosage form for mucosal immunization.
This notion was confirmed by the observation that induction of protective antiviral memory CTL in mucosal tissues depends on region-specific mucosal immunization (36).